Hub : Traits :

Medication: Simvastatin

131 significantly associated models · 49 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	61510619	63844736	4	1	8.3e-12	2.4e-12	1.0e+00	100	DOCK7
2	1	108854166	110742615	8	1	9.1e-36	7.0e-36	1.0e+00	100	PSRC1
3	2	20529948	21958745	1	1	8.6e-25	2.0e-25	1.0e+00	100	APOB
4	2	27467598	27949052	1	1	1.7e-09	1.2e-09	1.0e+00	100	FNDC4
5	2	43791363	44450524	2	2	6.1e-08	9.5e-18	1.3e-09	50	ABCG5 LRPPRC
6	5	73969058	75504243	2	1	1.6e-10	1.3e-10	1.0e-01	94	HMGCR
7	8	18003897	18505600	1	1	1.4e-09	7.4e-11	1.5e-02	86	NAT2
8	8	19547307	20071503	1	1	5.4e-08	6.2e-09	2.2e-03	72	LPL
9	9	135883620	136399075	1	1	3.7e-08	9.6e-09	3.1e-03	73	ABO
10	11	8725268	10159883	1	1	6.1e-08	2.0e-04	9.7e-03	52	IPO7
11	11	115953897	117745003	2	2	7.3e-15	7.8e-16	3.1e-01	98	PAFAH1B2 ZNF259
12	15	90730363	92135418	1	1	3.4e-08	7.2e-08	1.0e+00	100	FES
13	16	56749994	57261146	1	1	8.9e-08	8.9e-08	1.0e+00	100	CETP
14	16	71403083	72845749	4	1	2.2e-08	8.1e-08	1.0e+00	100	TXNL4B
15	19	10283932	12191233	7	3	3.3e-13	7.0e-38	5.3e-12	71	C19orf80 EPOR LDLR
16	19	44614208	46098885	4	5	9.6e-13	5.0e-70	3.1e-44	38	APOC2 BCAM PVRL2 TOMM40
17	19	48464978	49872085	3	1	1.7e-08	1.1e-08	1.3e-01	93	NTN5
18	20	39720830	40229720	1	1	3.8e-08	1.2e-06	1.6e-01	92	LPIN3
19	20	61989111	62912463	3	1	8.2e-09	2.4e-08	6.7e-01	99	OPRL1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
LDL Cholesterol	82.55	22	18	40.0	0.94	1.2e-11	ABCG5 ABO APOB APOC2 BCAM C19orf80 CETP DOCK7 EPOR FNDC4 HMGCR LDLR LPIN3 LRPPRC NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Triglycerides	54.56	11	8	17.8	0.72	1.2e-02	APOB APOC2 CETP DOCK7 FNDC4 LPL NAT2 PAFAH1B2 PVRL2 TXNL4B ZNF259
High cholesterol (Self-reported)	54.28	26	23	51.1	0.97	1.7e-17	ABCG5 ABO APOB APOC2 BCAM C19orf80 CETP DOCK7 EPOR FES FNDC4 HMGCR IPO7 LDLR LPIN3 LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
HDL Cholesterol	48.98	8	4	8.9	-0.63	9.5e-02	APOB APOC2 CETP LPL PSRC1 PVRL2 TOMM40 ZNF259
Medication: Cholesterol lowering	33.84	26	22	48.9	0.99	2.3e-22	ABCG5 ABO APOB APOC2 BCAM C19orf80 CETP DOCK7 EPOR FES FNDC4 HMGCR IPO7 LDLR LPIN3 LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Cholesterol lowering medication	28.70	23	19	42.2	0.99	2.1e-20	ABCG5 ABO APOB APOC2 BCAM C19orf80 DOCK7 EPOR FNDC4 HMGCR LDLR LPIN3 LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Medication: Atorvastatin	21.82	17	9	20.0	0.98	4.2e-12	ABO APOB BCAM C19orf80 DOCK7 EPOR FNDC4 HMGCR LPL LRPPRC NTN5 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Alzheimer’s Disease (including proxy)	14.31	4	4	8.9	0.99	9.8e-03	APOC2 BCAM PVRL2 TOMM40
Medication for cholesterol, blood pressure or diabetes	13.91	20	7	15.6	-0.96	8.4e-12	APOB BCAM C19orf80 CETP EPOR FES FNDC4 HMGCR IPO7 LDLR LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 TOMM40 TXNL4B ZNF259
Cardiovascular Disease	12.52	19	17	37.8	0.95	1.1e-10	ABCG5 APOB BCAM DOCK7 EPOR FES FNDC4 HMGCR LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Alzheimer’s Disease (in mother)	9.09	4	4	8.9	1.00	3.6e-04	APOC2 BCAM PVRL2 TOMM40
Coronary Artery Disease (CAD)	7.80	4	3	6.7	0.47	5.3e-01	EPOR LPL PSRC1 ZNF259
Angina (self-reported)	7.63	7	3	6.7	0.97	2.0e-04	ABCG5 APOC2 C19orf80 FES LPL OPRL1 PSRC1
Medication for cholesterol	7.62	11	2	4.4	-0.96	2.4e-06	DOCK7 FES FNDC4 HMGCR LDLR NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TXNL4B
Angina	7.54	7	2	4.4	0.97	2.7e-04	ABCG5 APOC2 C19orf80 FES LPL OPRL1 PSRC1
Medication: Aspirin	7.17	6	2	4.4	0.95	3.9e-03	C19orf80 EPOR FES LPL OPRL1 PSRC1
Illnesses of father: Heart disease	7.02	6	2	4.4	0.90	1.4e-02	ABO EPOR FES LPL OPRL1 PSRC1
Medication: Aspirin	6.98	6	1	2.2	0.95	3.6e-03	C19orf80 EPOR FES LPL OPRL1 PSRC1
Blood Red Count	5.52	7	4	8.9	-0.35	4.4e-01	ABCG5 ABO FES FNDC4 LPIN3 PVRL2 TXNL4B
Heart attack/myocardial infarction (self-reported)	5.24	4	1	2.2	0.95	4.7e-02	C19orf80 FES LPL PSRC1
Heart attack	5.22	4	1	2.2	0.95	4.6e-02	C19orf80 FES LPL PSRC1
Number of self-reported non-cancer illnesses	4.93	4	1	2.2	1.00	4.8e-03	ABO FNDC4 NTN5 OPRL1
Gout (self-reported)	4.76	1	1	2.2	0.00	1.0e+00	FNDC4
Vascular/heart problems diagnosed by doctor	4.70	3	3	6.7	0.00	1.0e+00	FES NTN5 OPRL1
Number of treatments/medications taken	4.58	6	0	0.0	0.95	4.3e-03	FES FNDC4 LDLR LRPPRC NTN5 PSRC1
Fasting Glucose	4.47	1	1	2.2	0.00	1.0e+00	FNDC4
Alcohol intake frequency.	4.22	3	2	4.4	0.00	1.0e+00	FNDC4 LPIN3 NTN5
Systolic Blood Pressure	4.12	7	3	6.7	0.76	4.7e-02	EPOR FES FNDC4 NTN5 OPRL1 PAFAH1B2 TOMM40
Medication: Allopurinol	4.05	1	1	2.2	0.00	1.0e+00	FNDC4
Blood Platelet Count	4.01	13	9	20.0	-0.04	9.0e-01	ABO APOC2 DOCK7 FNDC4 HMGCR LPIN3 LPL NTN5 PAFAH1B2 PVRL2 TOMM40 TXNL4B ZNF259
Blood clot in the leg (DVT)	3.90	1	1	2.2	0.00	1.0e+00	ABO
Deep venous thrombosis (DVT) (self-reported)	3.82	1	1	2.2	0.00	1.0e+00	ABO
Illnesses of father: None of the above (group 1)	3.73	1	1	2.2	0.00	1.0e+00	FES
Hypertension (Self-reported)	3.72	3	3	6.7	0.00	1.0e+00	FES NTN5 OPRL1
Medication: Blood pressure	3.70	2	1	2.2	0.00	1.0e+00	FES OPRL1
High blood pressure	3.63	3	2	4.4	0.00	1.0e+00	FES NTN5 OPRL1
Illnesses of mother	3.58	1	1	2.2	0.00	1.0e+00	FES
Medication: Atenolol	3.57	1	1	2.2	0.00	1.0e+00	FES
Alzheimer’s Disease (in father)	3.49	3	1	2.2	0.00	1.0e+00	APOC2 PVRL2 TOMM40
Heart disease (siblings)	3.48	3	0	0.0	0.00	1.0e+00	FES PSRC1 ZNF259
Father's age at death	3.43	3	0	0.0	0.00	1.0e+00	FES LPL PSRC1
Medication: Blood pressure	3.22	3	1	2.2	0.00	1.0e+00	FES NTN5 OPRL1
Type 2 Diabetes (T2D) (2018)	3.21	2	1	2.2	0.00	1.0e+00	FNDC4 LPL
Heart disease (mother)	3.11	1	0	0.0	0.00	1.0e+00	FES
High blood pressure (mother)	2.99	1	1	2.2	0.00	1.0e+00	FES
Pulse rate, automated reading	2.96	3	1	2.2	0.00	1.0e+00	APOB BCAM FNDC4
Illnesses of father: High blood pressure	2.96	1	1	2.2	0.00	1.0e+00	FES
Blood White Count	2.95	8	4	8.9	0.21	6.1e-01	ABO CETP DOCK7 FES FNDC4 LPIN3 PAFAH1B2 PVRL2
Medication: Ramipril	2.95	1	0	0.0	0.00	1.0e+00	FES
Systolic blood pressure, automated reading	2.93	2	2	4.4	0.00	1.0e+00	FES OPRL1
Medication: Metformin	2.82	3	1	2.2	0.00	1.0e+00	ABO FNDC4 LPL
Alcohol intake versus 10 years previously	2.81	2	1	2.2	0.00	1.0e+00	FNDC4 NTN5
Diabetes diagnosed by doctor	2.72	1	1	2.2	0.00	1.0e+00	FNDC4
High blood pressure (siblings)	2.71	2	1	2.2	0.00	1.0e+00	FES FNDC4
Illnesses of siblings	2.63	1	0	0.0	0.00	1.0e+00	FES
Trunk predicted mass	2.62	7	4	8.9	-0.63	1.3e-01	APOC2 CETP EPOR FNDC4 HMGCR NTN5 PSRC1
Trunk fat-free mass	2.61	7	4	8.9	-0.63	1.3e-01	APOC2 CETP EPOR FNDC4 HMGCR NTN5 PSRC1
Diastolic blood pressure, automated reading	2.61	3	1	2.2	0.00	1.0e+00	ABO C19orf80 FES
Arm fat-free mass (right)	2.57	6	2	4.4	-0.68	1.4e-01	CETP EPOR FNDC4 HMGCR NTN5 PSRC1
Arm predicted mass (right)	2.52	6	2	4.4	-0.67	1.5e-01	CETP EPOR FNDC4 HMGCR NTN5 PSRC1
Whole body water mass	2.50	4	2	4.4	-0.69	3.1e-01	EPOR FNDC4 HMGCR PSRC1
Arm predicted mass (left)	2.50	5	2	4.4	-0.77	1.2e-01	EPOR FNDC4 HMGCR NTN5 PSRC1
Diabetes (self-reported)	2.48	1	1	2.2	0.00	1.0e+00	FNDC4
Whole body fat-free mass	2.47	4	3	6.7	-0.70	3.0e-01	EPOR FNDC4 HMGCR PSRC1
Arm fat-free mass (left)	2.47	5	2	4.4	-0.76	1.4e-01	EPOR FNDC4 HMGCR NTN5 PSRC1
Diabetes (mother)	2.39	2	0	0.0	0.00	1.0e+00	FNDC4 PVRL2
Birth weight of first child	2.36	2	1	2.2	0.00	1.0e+00	FES OPRL1
Basal metabolic rate	2.36	4	2	4.4	-0.72	2.8e-01	EPOR FNDC4 HMGCR PSRC1
Leg predicted mass (left)	2.25	4	2	4.4	-0.89	1.1e-01	EPOR FES FNDC4 HMGCR
Pulse rate	2.25	1	1	2.2	0.00	1.0e+00	FNDC4
Diabetes (father)	2.24	1	0	0.0	0.00	1.0e+00	FNDC4
Leg fat-free mass (left)	2.24	4	2	4.4	-0.89	1.1e-01	EPOR FES FNDC4 HMGCR
Leg predicted mass (right)	2.24	5	2	4.4	-0.73	1.6e-01	EPOR FES FNDC4 HMGCR PSRC1
Leg fat-free mass (right)	2.23	5	2	4.4	-0.73	1.6e-01	EPOR FES FNDC4 HMGCR PSRC1
Crohns Disease (2017)	2.22	3	2	4.4	0.00	1.0e+00	DOCK7 FNDC4 NTN5
Impedance of leg (left)	2.20	6	4	8.9	0.30	5.6e-01	ABO FES FNDC4 HMGCR LPL OPRL1
Impedance of whole body	2.10	3	3	6.7	0.00	1.0e+00	FNDC4 HMGCR OPRL1
Impedance of arm (left)	2.08	4	2	4.4	0.94	6.1e-02	ABO FNDC4 HMGCR OPRL1
Impedance of leg (right)	2.02	5	4	8.9	0.62	2.7e-01	ABO FES FNDC4 HMGCR OPRL1
Serious illness, injury or assault of a close relative in last 2 years	2.01	1	0	0.0	0.00	1.0e+00	NTN5
Impedance of arm (right)	1.98	4	2	4.4	0.93	6.5e-02	ABO FNDC4 HMGCR OPRL1
Ovarian Cancer	1.96	2	0	0.0	0.00	1.0e+00	ABO OPRL1
Weight	1.96	4	2	4.4	-0.67	3.3e-01	EPOR FNDC4 HMGCR TXNL4B
Allergy	1.94	3	1	2.2	0.00	1.0e+00	ABO FES PVRL2
Body Mass Index (BMI) (2010)	1.93	1	0	0.0	0.00	1.0e+00	HMGCR
BMI	1.91	5	3	6.7	-0.40	5.1e-01	FNDC4 HMGCR LPL OPRL1 TXNL4B
Medication: Bendroflumethiazide	1.90	2	0	0.0	0.00	1.0e+00	FES NTN5
Irritable Bowel Disease (IBD)	1.89	3	1	2.2	0.00	1.0e+00	FNDC4 NTN5 OPRL1
Medication: Amlodipine	1.88	1	1	2.2	0.00	1.0e+00	FES
Hayfever, allergic rhinitis or eczema	1.86	3	0	0.0	1.00	5.1e-04	ABO FNDC4 PVRL2
Mouth/teeth dental problems: Dentures	1.86	1	1	2.2	0.00	1.0e+00	NTN5
Blood Eosinophil Count	1.78	11	5	11.1	-0.12	7.3e-01	ABO APOC2 BCAM DOCK7 EPOR LPL OPRL1 PAFAH1B2 PVRL2 TOMM40 ZNF259
Number of children fathered	1.78	1	0	0.0	0.00	1.0e+00	NTN5
Allergy or Eczema	1.75	5	0	0.0	0.77	7.3e-02	ABO APOC2 FES FNDC4 PVRL2
Birth weight	1.75	2	1	2.2	0.00	1.0e+00	FES NTN5
Arm fat mass (right)	1.73	4	1	2.2	-0.56	4.4e-01	FNDC4 HMGCR PVRL2 TXNL4B
Body mass index (BMI)	1.72	4	1	2.2	-0.60	4.0e-01	FNDC4 HMGCR PVRL2 TXNL4B
Arm fat mass (left)	1.72	4	1	2.2	-0.56	4.4e-01	FNDC4 HMGCR PVRL2 TXNL4B
Waist Hip Ratio (WHR)	1.71	5	2	4.4	0.99	2.1e-03	LPIN3 LPL LRPPRC NTN5 OPRL1
Waist circumference	1.68	4	1	2.2	-0.60	4.0e-01	FNDC4 HMGCR PVRL2 TXNL4B
Mouth/teeth dental problems	1.67	2	0	0.0	0.00	1.0e+00	DOCK7 NTN5
Hip circumference	1.67	4	2	4.4	-0.62	3.8e-01	FNDC4 HMGCR OPRL1 TXNL4B
Leg fat mass (right)	1.66	5	1	2.2	-0.60	2.9e-01	BCAM FNDC4 HMGCR PVRL2 TXNL4B
Leg fat mass (left)	1.65	5	1	2.2	-0.61	2.7e-01	BCAM FNDC4 HMGCR PVRL2 TXNL4B
Had menopause	1.63	1	0	0.0	0.00	1.0e+00	LPL
HbA1C	1.62	1	0	0.0	0.00	1.0e+00	ABO
Rheumatoid Arthritis	1.62	1	0	0.0	0.00	1.0e+00	OPRL1
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.62	2	0	0.0	0.00	1.0e+00	ABO PVRL2
Headache pain in last month	1.60	1	0	0.0	0.00	1.0e+00	FES
Relative age of first facial hair	1.57	1	1	2.2	0.00	1.0e+00	FNDC4
Breast Cancer	1.56	3	0	0.0	0.00	1.0e+00	ABO FES OPRL1
Alcohol usually taken with meals	1.55	2	0	0.0	0.00	1.0e+00	FES LPIN3
Ulcerative Colitis (UC)	1.54	1	1	2.2	0.00	1.0e+00	OPRL1
Had other major operations	1.53	1	0	0.0	0.00	1.0e+00	ABCG5
Seen doctor (GP) for nerves, anxiety, tension or depression	1.53	1	1	2.2	0.00	1.0e+00	LPIN3
Arm fat percentage (right)	1.49	4	1	2.2	-0.33	6.7e-01	ABO HMGCR PVRL2 TXNL4B
Arm fat percentage (left)	1.49	4	1	2.2	-0.35	6.5e-01	ABO HMGCR PVRL2 TXNL4B
Hand grip strength (right)	1.48	3	0	0.0	0.00	1.0e+00	FNDC4 LRPPRC PVRL2
Whole body fat mass	1.48	4	1	2.2	-0.56	4.4e-01	BCAM HMGCR PVRL2 TXNL4B
Hand grip strength (left)	1.47	2	0	0.0	0.00	1.0e+00	FES PVRL2
Number of incorrect matches in round	1.47	2	0	0.0	0.00	1.0e+00	FES NAT2
Comparative height size at age 10	1.47	4	2	4.4	-0.77	2.3e-01	FNDC4 IPO7 NTN5 PSRC1
Ulcerative Colitis	1.46	1	0	0.0	0.00	1.0e+00	PAFAH1B2
Peak expiratory flow (PEF)	1.42	2	2	4.4	0.00	1.0e+00	ABO NTN5
Average weekly spirits intake	1.41	1	0	0.0	0.00	1.0e+00	NTN5
Breastfed as a baby	1.41	1	0	0.0	0.00	1.0e+00	FES
Primary Biliary Cirrhosis	1.40	1	0	0.0	0.00	1.0e+00	EPOR
Number of operations (self-reported)	1.40	1	0	0.0	0.00	1.0e+00	ABCG5
Bipolar Disorder (2018)	1.39	1	0	0.0	0.00	1.0e+00	FNDC4
Bipolar Disorder or Schizophrenia	1.38	1	1	2.2	0.00	1.0e+00	FES
Crohns Disease (2012)	1.38	2	0	0.0	0.00	1.0e+00	DOCK7 FNDC4
Trunk fat mass	1.35	4	1	2.2	-0.57	4.3e-01	BCAM HMGCR PVRL2 TXNL4B
Chronic bronchitis/emphysema (mother)	1.35	1	0	0.0	0.00	1.0e+00	BCAM
Smoking Status	1.33	1	0	0.0	0.00	1.0e+00	FES
Respiratory disease	1.33	2	0	0.0	0.00	1.0e+00	ABO FES
Forced expiratory volume in 1-second (FEV1), Best measure	1.28	3	0	0.0	0.00	1.0e+00	ABO EPOR PVRL2
Risk taking	1.28	1	0	0.0	0.00	1.0e+00	LRPPRC
Forced expiratory volume in 1-second (FEV1)	1.27	3	1	2.2	0.00	1.0e+00	ABO EPOR PVRL2
Body fat percentage	1.26	4	1	2.2	-0.61	3.9e-01	BCAM HMGCR PVRL2 TXNL4B
Heel T-Score	1.24	5	2	4.4	-0.87	5.5e-02	ABO DOCK7 HMGCR LPIN3 PSRC1
Sitting height	1.24	5	1	2.2	-0.84	7.8e-02	ABCG5 ABO FNDC4 NTN5 TXNL4B
Leg fat percentage (right)	1.23	3	1	2.2	0.00	1.0e+00	BCAM HMGCR TXNL4B
Back pain experienced in last month	1.23	1	0	0.0	0.00	1.0e+00	APOB
Schizophrenia (2018)	1.22	1	1	2.2	0.00	1.0e+00	FES
Leg fat percentage (left)	1.22	3	1	2.2	0.00	1.0e+00	BCAM HMGCR TXNL4B
Lung FVC	1.19	4	2	4.4	-0.47	5.3e-01	ABO FNDC4 OPRL1 PVRL2
Asthma (self-reported)	1.19	1	0	0.0	0.00	1.0e+00	ABO
Trunk fat percentage	1.18	4	1	2.2	-0.60	4.0e-01	BCAM HMGCR PVRL2 TXNL4B
Schizophrenia (2014)	1.16	1	1	2.2	0.00	1.0e+00	FES
Forced vital capacity (FVC), Best measure	1.16	3	0	0.0	0.00	1.0e+00	ABO EPOR PVRL2
Guilty feelings	1.15	1	0	0.0	0.00	1.0e+00	LPIN3
Heel bone mineral density (BMD) T-score, automated (left)	1.12	1	0	0.0	0.00	1.0e+00	ABO
Comparative body size at age 10	1.11	2	1	2.2	0.00	1.0e+00	FNDC4 NTN5
Heel bone mineral density (BMD) T-score, automated (right)	1.10	1	0	0.0	0.00	1.0e+00	ABO
Asthma	1.10	1	0	0.0	0.00	1.0e+00	ABO
Lung FEV1/FVC ratio	1.08	2	2	4.4	0.00	1.0e+00	NTN5 PSRC1
Forced vital capacity (FVC)	1.08	3	1	2.2	0.00	1.0e+00	ABO EPOR PVRL2
Sensitivity / hurt feelings	1.06	1	0	0.0	0.00	1.0e+00	FES
Hypothyroidism (self reported)	1.02	1	0	0.0	0.00	1.0e+00	NTN5
Hair/balding pattern: Pattern 4	1.00	1	0	0.0	0.00	1.0e+00	LPIN3
Standing height	0.98	6	2	4.4	-0.67	1.5e-01	ABCG5 APOC2 EPOR FNDC4 NTN5 PSRC1
Schizophrenia vs Biploar Disorder	0.96	1	0	0.0	0.00	1.0e+00	FNDC4
Height	0.95	10	6	13.3	-0.74	1.5e-02	ABCG5 ABO APOC2 EPOR FES FNDC4 LPL NTN5 PSRC1 ZNF259
Chronotype (morning person)	0.91	1	0	0.0	0.00	1.0e+00	NTN5
Age when periods started (menarche)	0.91	1	0	0.0	0.00	1.0e+00	NTN5
Hair/balding pattern: Pattern 3	0.84	1	0	0.0	0.00	1.0e+00	LPIN3
Intelligence (Savage-Jansen 2018)	0.83	1	0	0.0	0.00	1.0e+00	TXNL4B
Qualifications: None of the above	0.81	1	0	0.0	0.00	1.0e+00	DOCK7
Tanning	0.28	2	1	2.2	0.00	1.0e+00	EPOR FNDC4
Hair Pigment	0.21	4	1	2.2	0.75	2.5e-01	EPOR FES FNDC4 OPRL1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.271	1.8
GTEx	Liver	2	0.279	1.7
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.197	1.7
GTEx	Stomach	2	0.138	1.6
GTEx	Vagina	1	0.157	1.6
GTEx	Whole Blood	4	0.201	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	1	0.091	1.6
The Cancer Genome Atlas	Colon Adenocarcinoma	5	0.242	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	6	0.146	1.6
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	2	0.126	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.6
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.238	1.6
GTEx	Adipose Visceral Omentum	1	0.049	1.5
GTEx	Adrenal Gland	0	0.000	1.5
GTEx	Artery Aorta	3	0.101	1.5
GTEx	Artery Coronary	0	0.000	1.5
GTEx	Artery Tibial	3	0.080	1.5
GTEx	Brain Cerebellum	1	0.050	1.5
GTEx	Brain Frontal Cortex BA9	0	0.000	1.5
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.5
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.5
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.5
GTEx	Cells Transformed fibroblasts	5	0.119	1.5
GTEx	Esophagus Mucosa	7	0.211	1.5
GTEx	Esophagus Muscularis	3	0.093	1.5
GTEx	Lung	0	0.000	1.5
GTEx	Muscle Skeletal	2	0.069	1.5
GTEx	Ovary	0	0.000	1.5
GTEx	Prostate	0	0.000	1.5
GTEx	Skin Not Sun Exposed Suprapubic	2	0.081	1.5
GTEx	Skin Sun Exposed Lower leg	4	0.110	1.5
GTEx	Small Intestine Terminal Ileum	0	0.000	1.5
GTEx	Testis	0	0.000	1.5
GTEx	Thyroid	1	0.025	1.5
ROSMAP	Brain Pre-frontal Cortex	5	0.114	1.5
YFS	Blood	5	0.108	1.5
CommonMind	Brain Pre-frontal Cortex	6	0.112	1.5
The Cancer Genome Atlas	Breast Invasive Carcinoma	4	0.091	1.5
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.5
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	5	0.244	1.5
The Cancer Genome Atlas	Lung Adenocarcinoma	2	0.068	1.5
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	4	0.241	1.5
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.5
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.5
The Cancer Genome Atlas	Soft Tissue Sarcoma	1	0.094	1.5
The Cancer Genome Atlas	Thyroid Carcinoma	5	0.097	1.5
GTEx	Adipose Subcutaneous	1	0.029	1.4
GTEx	Brain Caudate basal ganglia	0	0.000	1.4
GTEx	Brain Cerebellar Hemisphere	1	0.067	1.4
GTEx	Brain Cortex	0	0.000	1.4
GTEx	Brain Hippocampus	0	0.000	1.4
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.4
GTEx	Breast Mammary Tissue	0	0.000	1.4
GTEx	Colon Sigmoid	0	0.000	1.4
GTEx	Colon Transverse	0	0.000	1.4
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.4
GTEx	Heart Atrial Appendage	0	0.000	1.4
GTEx	Heart Left Ventricle	0	0.000	1.4
GTEx	Nerve Tibial	2	0.046	1.4
GTEx	Pancreas	2	0.123	1.4
GTEx	Pituitary	0	0.000	1.4
GTEx	Spleen	1	0.071	1.4
METSIM	Adipose	2	0.043	1.4
NTR	Blood	2	0.083	1.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	0	0.000	1.4
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.4
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	2	0.073	1.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	6	0.139	1.4
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	3	0.120	1.4
The Cancer Genome Atlas	Prostate Adenocarcinoma	6	0.130	1.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.4
GTEx	Brain Hypothalamus	0	0.000	1.3
GTEx	Brain Putamen basal ganglia	0	0.000	1.3
GTEx	Uterus	0	0.000	1.3